TipRanks
Advertisement
Advertisement

HUMA Stock Latest News

Humacyte says hospitals ordering Symvess rose 44% in Q3 to 49
The FlyHumacyte says hospitals ordering Symvess rose 44% in Q3 to 49
6d ago
HUMA
Flutter upgraded, AppFolio downgraded: Wall Street’s top analyst calls
PremiumThe Fly
Flutter upgraded, AppFolio downgraded: Wall Street’s top analyst calls
14d ago
EW
OC
Humacyte initiated with an Equal Weight at Barclays
PremiumThe Fly
Humacyte initiated with an Equal Weight at Barclays
15d ago
HUMA
Humacyte Bolsters Board for Upcoming Commercial Expansion
PremiumCompany Announcements
Humacyte Bolsters Board for Upcoming Commercial Expansion
23d ago
8K
HUMA
Humacyte announces addition of Coward, Kuznik to board
PremiumThe Fly
Humacyte announces addition of Coward, Kuznik to board
23d ago
HUMA
Humacyte announces FDA extension of expiration dating period for Symvess
PremiumThe FlyHumacyte announces FDA extension of expiration dating period for Symvess
1M ago
HUMA
Humacyte Earnings Call: Clinical Wins vs Cash Burn
Premium
Company Announcements
Humacyte Earnings Call: Clinical Wins vs Cash Burn
2M ago
HUMA
Humacyte confirms plans for ATEV supplemental biologic license application
Premium
The Fly
Humacyte confirms plans for ATEV supplemental biologic license application
2M ago
HUMA
Humacyte Earns Buy Rating as Phase 3 V007 Data Publication Strengthens Regulatory and Commercial Outlook
PremiumRatings
Humacyte Earns Buy Rating as Phase 3 V007 Data Publication Strengthens Regulatory and Commercial Outlook
2M ago
HUMA
Humacyte publishes V007 results in The Lancet Digital Health
PremiumThe Fly
Humacyte publishes V007 results in The Lancet Digital Health
2M ago
HUMA
Humacyte reports Q2 EPS (16c), consensus (10c)
PremiumThe Fly
Humacyte reports Q2 EPS (16c), consensus (10c)
2M ago
HUMA
Humacyte price target lowered to $1 from $2 at Benchmark
PremiumThe Fly
Humacyte price target lowered to $1 from $2 at Benchmark
2M ago
HUMA
Humacyte Faces Nasdaq Non-Compliance Warning as Share Price Risks Delisting and Future Capital Constraints
PremiumCompany AnnouncementsHumacyte Faces Nasdaq Non-Compliance Warning as Share Price Risks Delisting and Future Capital Constraints
2M ago
HUMA
Humacyte’s Symvess Trauma Study: Real-World Data Push With Investor Upside
Premium
Company Announcements
Humacyte’s Symvess Trauma Study: Real-World Data Push With Investor Upside
2M ago
HUMA
Analyst Reiterates Buy on Humacyte, Maintains $4 Price Target Amid Dialysis Growth and Regulatory Catalysts
Premium
Ratings
Analyst Reiterates Buy on Humacyte, Maintains $4 Price Target Amid Dialysis Growth and Regulatory Catalysts
2M ago
HUMA
HUMA Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
HUMA Upcoming Earnings Report: What to Expect?
2M ago
HUMA
Humacyte Receives Nasdaq Notice on Bid Price Noncompliance
PremiumCompany Announcements
Humacyte Receives Nasdaq Notice on Bid Price Noncompliance
3M ago
8K
HUMA
Buy Rating Reaffirmed on Humacyte as FDA Clears First-in-Human CABG Study; $2 Price Target Maintained
PremiumRatings
Buy Rating Reaffirmed on Humacyte as FDA Clears First-in-Human CABG Study; $2 Price Target Maintained
3M ago
HUMA
Humacyte announces FDA acceptance of CTEV IND application
PremiumThe Fly
Humacyte announces FDA acceptance of CTEV IND application
3M ago
HUMA
Humacyte price target lowered to $1.25 from $1.50 at TD Cowen
PremiumThe FlyHumacyte price target lowered to $1.25 from $1.50 at TD Cowen
4M ago
HUMA
Humacyte Announces Underwritten Public Equity Offering to Fund Growth
Premium
Company Announcements
Humacyte Announces Underwritten Public Equity Offering to Fund Growth
4M ago
8K
HUMA
Humacyte price target raised to $4 from $3 at H.C. Wainwright
Premium
The Fly
Humacyte price target raised to $4 from $3 at H.C. Wainwright
4M ago
HUMA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >